STOCK TITAN
  1. Home
  2. News
  3. EDAP

EDAP TMS S.A. - EDAP STOCK NEWS

Welcome to our dedicated news page for EDAP TMS S.A. (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on EDAP TMS S.A..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EDAP TMS S.A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EDAP TMS S.A.'s position in the market.

News
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
Rhea-AI Summary
EDAP TMS SA announces final results from the HIFI Study comparing outcomes of Focal One® HIFU versus Radical Prostatectomy to be presented at the 119th AUA Annual Meeting. The study is the largest clinical trial comparing the two treatments for prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
News
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) reported strong financial results for Q4 2023 and full-year 2023, with record total revenue and HIFU revenue growth. The company highlighted significant U.S. Focal One HIFU procedure growth and positive market demand for their robotic energy-based therapies, projecting a promising outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
earnings
-
News
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) will release its financial results for Q4 and full-year 2023 on March 27, 2024. The company, a leader in robotic energy-based therapies, will host a conference call and webcast with top executives. Details for participation are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
earnings
News
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Rhea-AI Summary
EDAP TMS SA CEO to Present at Oppenheimer Healthcare MedTech & Services Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
conferences
-
News
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
Rhea-AI Summary
EDAP TMS SA's Focal One platform, granted Breakthrough Device designation by the FDA, aims to address deep infiltrating endometriosis, a significant unmet medical need in women's health. Positive Phase 2 study results show a decrease in symptoms and improvement in quality of life, supporting the safety and efficacy of the Focal One HIFU therapy. The ongoing Phase 3 study is expected to provide further insights into the treatment's effectiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none
-
News
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues
Rhea-AI Summary
EDAP TMS SA reports record full-year 2023 revenue of EUR 60.4 million, driven by 31.7% HIFU growth, with a strong Q4 revenue of EUR 19.6 million and 136% U.S. Focal One HIFU procedure growth. CEO Ryan Rhodes highlights increased demand and business momentum for Focal One Robotic HIFU in prostate cancer management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.72%
Tags
none
News
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
Rhea-AI Summary
EDAP TMS SA has completed enrollment in its Phase 3 study evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis. The study, which included a sham-controlled arm, is expected to yield results in the second half of 2024. Positive results from the Phase 2 study showed a significant decrease in symptoms and improved quality of life for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.66%
Tags
clinical trial
-
News
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales. The company experienced robust demand for its Focal One robotic HIFU technology and had a record quarter for sales of ExactVu™ Micro-Ultrasound systems used for prostate biopsy. The placements show strong interest among both academic medical centers and community hospitals. The CEO, Ryan Rhodes, expressed confidence in Focal One becoming a necessary solution in the management of prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
-
News
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) appoints new Chief Financial Officer and Global Chief Accounting Officer to support strategic growth initiatives in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
management
News
EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) receives a favorable recommendation from the French National Authority for Health for the reimbursement of high-intensity focused ultrasound (HIFU) therapy in the treatment of prostate cancer, marking a significant milestone in securing final reimbursement in France. The positive opinion is based on the outstanding safety and favorable clinical outcomes from the Focal One Robotic HIFU in the HIFI study, which included more than 3,000 prostate cancer patients. This decision brings the company closer to expanding treatment options for physicians and their patients with the leading Focal One HIFU technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
Stock EDAP logo
EDAP TMS S.A.

Nasdaq:EDAP

EDAP Rankings

#3486 Ranked by Market Cap
#3917 Ranked by Stock Gains
N/A Ranked by Dividends

EDAP Stock Data

280.88M
29.56M
43.11%
0.28%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
France
Lyon

About EDAP

global leader in therapeutic ultrasound and present in the market for more than 30 years, edap tms (nasdaq: edap) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. edap tms is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. by constantly investing in research & development and partnering with internationally renowned medical research institutions, edap tms has developed a strong valuable patent portfolio based on its innovative technologies. with its complete range of robotic hifu devices, edap tms is the most innovative company in minimally-invasive treatment for localized prostate cancer. by combining the latest technologies in imaging and treatment modalities, edap tms just introduced the focal one® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing ablatherm® hifu. as a pioneer and ke